Skip to content

Role of Pathadya Churna in Ulcerative colitis

Clinical Study of Pathadya Churna in the management of Ulcerative Colitis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048648
Enrollment
50
Registered
2023-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K519- Ulcerative colitis, unspecified

Interventions

None listed

Sponsors

Shradha Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have mild to moderate ulcerative colitis , with a current simple clinical colitis activity index greater then or equal to 3 and less then or equal to 11. 2. Patients whose diagnosis confirmed with sigmoidoscopy/colonoscopy.

Exclusion criteria

Exclusion criteria: 1. Patients who are in remission from ulcerative colitis or who have a simple clinical colitis activity index 0 - 2. 2. Patients who have severe ulcerative colitis or simple clinical colitis activity index of 12 or above. 3. Patients who are noncompliant with medication or regular follow up visits or who are unable to or unwilling to record response. 4. Patients with comorbid illness including DM, Stage III or above CHF, Chronic pancreatitis, Severe liver or renal disease. 5. Patients with anemia ( Hb 6. Patients with history of malignancy 7. Patients who are currently pregnant or nursing

Design outcomes

Primary

MeasureTime frame
Blood in Stool and Pain in abdomen Studied.Timepoint: At duration of 30 days, 60 days, 90 days.

Secondary

MeasureTime frame
Tenesmus, Appetite, Urgency of Defecation ,Bowel frequency (Day & Night) Studied. Timepoint: At Durations of 30 days, 60 days, 90 days.

Countries

India

Contacts

Public ContactShradha Singh

Faculty of Ayurveda IMS-BHU

drsrpedhekar@gmail.com9423241800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026